Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The companys lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The companys product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
January 21, 2021
RegMed Investors’ (RMi) pre-open: snails crawl at a slow pace; will there be a slime trail?
January 20, 2021
RegMed Investors’ (RMi) closing bell: on what news is moving “our” sector downward?
January 19, 2021
RegMed Investors’ (RMi) closing bell: rebound follows decline and a holiday
January 15, 2021
RegMed Investors’ (RMi) closing bell: momentum shifts into reverse
January 15, 2021
RegMed Investors’ (RMi) pre-open: when you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started
January 14, 2021
RegMed Investors’ (RMi) closing bell: the sector gains as markets finish lower
January 14, 2021
RegMed Investors’ (RMi) pre-open: sector resembles a dine and dash scenario
January 11, 2021
RegMed Investors’ (RMi) closing bell: Washington tension drains sentiment
January 11, 2021
RegMed Investors’ (RMi) pre-open: Volatility, valuations, news and prelim earnings and a spin-off to hoot
January 8, 2021
RegMed Investors’ (RMi) closing bell: the finger came out of the dike of record highs
35 companies, 1 interpreter!
Insight, foresight and recommendation
Verastem (VSTM) -- Opened 2018 at $3.21, started February at $3.55 and March at $3.05 with a high of $3.24 on 3/6 - neeeds news which always stimulates volume and pricing offsetting complacency in share pricing ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.